Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.74% | -11.64% | -10.85% | 7.03% | 31.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.22% | 40.55% | 59.67% | 96.39% | 132.76% |
| Operating Income | 6.22% | -40.55% | -59.67% | -96.39% | -132.76% |
| Income Before Tax | -19.17% | -75.63% | -110.56% | -141.28% | -0.21% |
| Income Tax Expenses | -37.04% | -66.34% | -46.53% | -46.53% | -46.53% |
| Earnings from Continuing Operations | -19.16% | -75.59% | -110.50% | -141.19% | -0.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.16% | -75.59% | -110.50% | -141.19% | -0.20% |
| EBIT | 6.22% | -40.55% | -59.67% | -96.39% | -132.76% |
| EBITDA | 6.46% | -40.33% | -58.99% | -94.90% | -131.23% |
| EPS Basic | -19.07% | -74.40% | -93.70% | -53.47% | 72.64% |
| Normalized Basic EPS | 2.72% | -46.43% | -52.04% | -30.21% | 4.04% |
| EPS Diluted | -19.52% | -74.98% | -93.51% | -53.34% | 72.67% |
| Normalized Diluted EPS | 2.72% | -46.43% | -52.04% | -30.21% | 4.04% |
| Average Basic Shares Outstanding | 0.39% | 1.00% | 9.07% | 34.82% | 81.82% |
| Average Diluted Shares Outstanding | 0.39% | 1.00% | 9.07% | 34.82% | 81.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |